(Q33399706)

English

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

Federica Cavallo

object named as

Federica Cavallo

3

0 references

Massimo Offidani

object named as

Massimo Offidani

1

0 references

Antonio Palumbo

14

object named as

Antonio Palumbo

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Claudia Polloni

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anna Marina Liberati

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stelvio Ballanti

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stefano Pulini

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Massimo Catarini

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Francesco Alesiani

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laura Corvatta

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Silvia Gentili

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Patrizia Caraffa

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mario Boccadoro

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Pietro Leoni

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

16 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1722-1727

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

The epigenomics of cancer

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2012.664844

21 January 2018

Identifiers

10.3109/10428194.2012.664844

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33399706&oldid=1837014657"